β-Thujaplicin modulates estrogen receptor signaling and inhibits proliferation of human breast cancer cells
- Authors
- Ko, Jiwon; Bao, Cheng; Park, Hyun-Chang; Kim, Minchae; Choi, Hyung-Kyoon; Kim, Young-Suk; Lee, Hong Jin
- Issue Date
- Jun-2015
- Publisher
- TAYLOR & FRANCIS LTD
- Keywords
- beta-thujaplicin; ubiquitination; cyclin D1; breast cancer; estrogen receptor
- Citation
- BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, v.79, no.6, pp 1011 - 1017
- Pages
- 7
- Journal Title
- BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
- Volume
- 79
- Number
- 6
- Start Page
- 1011
- End Page
- 1017
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/9451
- DOI
- 10.1080/09168451.2015.1008978
- ISSN
- 0916-8451
1347-6947
- Abstract
- beta-Thujaplicin, one of the major constituents in Chamaecyparis obtusa, has been demonstrated to exert different health beneficial efficacy, but the role of beta-thujaplicin in regulating mammary tumorigenesis has not been investigated. In this study, we found that beta-thujaplicin significantly suppressed the proliferation through arresting the cell cycle transition from G1 to S phase as well as inhibited the expression of cell cycle-related proteins, cyclin D1, and cyclin-dependent kinase 4 (CDK4) in MCF-7 and T47D luminal subtype breast cancer cells. In addition, estrogen receptor alpha (ER-alpha) was down-regulated by beta-thujaplicin via enhanced proteolysis by ubiquitination, which led to cell growth inhibition. These results suggest that beta-thujaplicin may be considered as a potent agent regulating the hormone sensitive mammary tumorigenesis.
- Files in This Item
-
- Appears in
Collections - College of Pharmacy > School of Pharmacy > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.